Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Synapsinae
- Development stage
- Unknown
- Lead developer
- SyneuRx International
- Modality
- Small Molecules
01
Overview
Synapsinae (SNG-12) is a small molecule glycine transporter 1 (GlyT-1) inhibitor developed by SyneuRx International (Taiwan) Corp. for the treatment of major depressive disorder (MDD) and suicidal ideation. The drug's mechanism of action involves blocking the reuptake of glycine, an obligatory co-agonist of the N-methyl-D-aspartate (NMDA) receptor, thereby increasing synaptic glycine levels and indirectly enhancing NMDA receptor signaling. This approach aims to address glutamatergic dysfunction associated with depressive symptoms and suicidality. As of late 2022, Synapsinae was in Phase 3 clinical development for MDD and suicidal ideation, and in Phase 2 for psychotic disorders and dementia.
02
Targets
SLC6A9 (Glycine transporter type 1)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on Synapsinae.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synapsinae.